Syngene Viral Testing Facility – Striving For Excellence
Source: Syngene International Ltd.
Biologics are a key driver of future biotech industry growth. The domain is expected to expand at 16-20% per year for next few years, with the upcoming patent expiration of some biologics therapies giving a shot in the arm to manufacturing services. Novel molecules for therapies targeting the oncology segment will also be a key growth driver.
Explore the quality services and in-house safety program that Syngene provides, along with the company's service to the nation in the fight against the COVID-19 virus.
access the Brochure!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.
Subscribe to Pharmaceutical Online
X
Subscribe to Pharmaceutical Online
Syngene International Ltd.
This website uses cookies to ensure you get the best experience on our website. Learn more